Drugs / KHK6640
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03093519 | Mar → Dec 2017 | Alzheimer disease | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02377713 | Mar 2015 → Sep 2016 | Alzheimer disease | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02127476 | Jul 2014 → May 2017 | Alzheimer disease | Kyowa Kirin, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-06-18 | Kyowa Kirin, Inc. | Regulatory Kyowa Hakko Kirin initiates a Phase I Trial of KHK6640 for Alzheimer's Disease in Europe kyowakirin.com ↗
Kyowa Hakko Kirin submitted a Clinical Trial Application for a Phase I trial to confirm the safety and tolerability of this antibody in patients with prodromal/mild/moderate Alzheimer's disease, and the application has been accepted by the regulatory authority of Belgium. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-06-18 | Kyowa Kirin, Inc. | Kyowa Hakko Kirin initiates a Phase I Trial of KHK6640 for Alzheimer's Disease in Europe kyowakirin.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KHK6640 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02127476 ↗ |
| Route | Intravenous | “Intravenous administration” NCT03093519 ↗ |